Marie-Jeanne T F D Vrancken Peeters
Overview
Explore the profile of Marie-Jeanne T F D Vrancken Peeters including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
1133
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Spoor J, Vrancken Peeters M, Oldenburg H, Bleiker E, van Leeuwen F
Ann Epidemiol
. 2024 Apr;
94:1-8.
PMID: 38609024
Background: Data collection by mailing questionnaires to the study population is one of the main research methods in epidemiologic studies. As participation rates are decreasing, easy-to-implement and cost-effective strategies to...
12.
van Olmen J, Jacobs C, Bartels S, Loo C, Sanders J, Vrancken Peeters M, et al.
Breast
. 2024 Apr;
75:103726.
PMID: 38599047
Objective: This study aims to evaluate the response to and surgical benefits of neoadjuvant endocrine therapy (NET) in ER+/HER2-breast cancer patients who are clinically high risk, but genomic low risk...
13.
van der Voort A, Louis F, van Ramshorst M, Kessels R, Mandjes I, Kemper I, et al.
Lancet Oncol
. 2024 Apr;
25(5):603-613.
PMID: 38588682
Background: Patients with stage II-III HER2-positive breast cancer have good outcomes with the combination of neoadjuvant chemotherapy and HER2-targeted agents. Although increasing the number of chemotherapy cycles improves pathological complete...
14.
de Wild S, Koppert L, van Nijnatten T, Kooreman L, Vrancken Peeters M, Smidt M, et al.
Br J Surg
. 2024 Mar;
111(3).
PMID: 38531689
Background: In node-positive (cN+) breast cancer treated with neoadjuvant systemic therapy, combining sentinel lymph node biopsy and targeted lymph node excision, that is targeted axillary dissection, increases accuracy. Targeted axillary...
15.
Bartels S, van Olmen J, Scholten A, Bekers E, Drukker C, Vrancken Peeters M, et al.
Eur J Cancer
. 2024 Feb;
201:113924.
PMID: 38364628
Aim: The aim of our study is to analyze patterns in treatment and outcome in a population-based series of patients with borderline and malignant phyllodes tumors (PT). Material And Methods:...
16.
van Hemert A, van Loevezijn A, Bosman A, Vlahu C, Loo C, Vrancken Peeters M, et al.
Breast Cancer Res Treat
. 2024 Jan;
204(3):497-507.
PMID: 38189904
Introduction: Breast cancer patients with invasive lobular carcinoma (ILC) have an increased risk of positive margins after surgery and often show little response to neoadjuvant chemotherapy (NAC). We aimed to...
17.
de Wild S, Koppert L, de Munck L, Vrancken Peeters M, Siesling S, Smidt M, et al.
Breast Cancer Res Treat
. 2023 Dec;
204(2):277-288.
PMID: 38133707
Purpose: In breast cancer, neoadjuvant chemotherapy (NAC) can downstage the nodal status, and can even result in a pathological complete response, which is associated with improved prognosis. This study aimed...
18.
Veluponnar D, Dashtbozorg B, Jong L, Geldof F, Da Silva Guimaraes M, Vrancken Peeters M, et al.
Biomed Opt Express
. 2023 Oct;
14(8):4017-4036.
PMID: 37799696
During breast-conserving surgeries, it remains challenging to accomplish adequate surgical margins. We investigated different numbers of fibers for fiber-optic diffuse reflectance spectroscopy to differentiate tumorous breast tissue from healthy tissue...
19.
Vliek S, Hilbers F, van Werkhoven E, Mandjes I, Kessels R, Kleiterp S, et al.
NPJ Breast Cancer
. 2023 Sep;
9(1):75.
PMID: 37689749
Exploratory analyses of high-dose alkylating chemotherapy trials have suggested that BRCA1 or BRCA2-pathway altered (BRCA-altered) breast cancer might be particularly sensitive to this type of treatment. In this study, patients...
20.
van Olmen J, Beerthuizen A, Bekers E, Viegen I, Drukker C, Vrancken Peeters M, et al.
Ann Surg Oncol
. 2023 Aug;
30(13):8344-8352.
PMID: 37639031
Background: Phyllodes tumors (PTs) are rare tumors of the breast. The current National Comprehensive Cancer Network (NCCN) guidelines recommend excision of benign PTs, accepting close or positive margins. Controversy about...